TNDMNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
TANDEM DIABETES CARE INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$16.38+0.14 (+0.86%)
Close on Oct 19, 2026
- Market cap
- $1.13B
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$1.59 (+10.75%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
TANDEM DIABETES CARE INC grew revenue 4.0% to $1.04B over the twelve months to Jun 30, 2026. Free cash flow was -$26.62M.
Revenue
$1.04B
+4.0% vs. a year earlier
Operating income
-$45.80M
TTM Q2 2026
Free cash flow
-$26.62M
TTM Q2 2026
EPS, diluted
-$0.93
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $1.13B
- P/E ratio
- –
- Price to sales
- 1.09
- Price to book
- 8.67
- Dividend yield
- –
- Free cash flow yield
- -2.35%
Fundamentals
- Revenue
- $1.04B
- Net income
- -$63.32M
- EPS, diluted
- -$0.93
- Free cash flow
- -$26.62M
- Book value per share
- $1.89
- Diluted shares
- 69M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
$1.04B+4.0% YoY
Gross profit
$583.32M+10.8% YoY
Operating income
-$45.80M
Net income
-$63.32M
EPS, diluted
-$0.93
Free cash flow
-$26.62M
Reported periodTrailing twelve months